Silence Therapeutics (NASDAQ:SLN) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a report published on Thursday, Benzinga reports. The firm currently has a $75.00 price objective on the stock.

A number of other research analysts have also commented on the company. Morgan Stanley reiterated an overweight rating and issued a $45.00 price objective on shares of Silence Therapeutics in a research report on Monday, April 22nd. Chardan Capital reiterated a buy rating and issued a $42.00 price objective on shares of Silence Therapeutics in a research report on Friday, May 17th.

Silence Therapeutics Price Performance

NASDAQ SLN opened at $18.90 on Thursday. The firm has a market cap of $565.68 million, a PE ratio of -16.29 and a beta of 1.34. Silence Therapeutics has a one year low of $4.84 and a one year high of $27.72. The stock’s 50 day simple moving average is $21.50 and its 200 day simple moving average is $20.75.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings results on Thursday, May 16th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.18. The business had revenue of $15.73 million for the quarter, compared to analyst estimates of $4.53 million. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. As a group, equities analysts expect that Silence Therapeutics will post -1.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Silence Therapeutics in the 4th quarter valued at $110,000. Lynx1 Capital Management LP acquired a new position in shares of Silence Therapeutics in the 3rd quarter valued at $2,315,000. Parkman Healthcare Partners LLC lifted its stake in shares of Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,063 shares during the period. Vivo Capital LLC acquired a new position in shares of Silence Therapeutics in the 4th quarter valued at $8,862,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Silence Therapeutics in the 1st quarter valued at $13,575,000. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.